S. 1954

Biosimilar Red Tape Elimination Act

Health, Education, Labor, and Pensions Committee · Sen. Mike Lee (R-UT)

The bill would automatically deem all biosimilars approved by the FDA to be interchangeable with their original brand-name biological products, eliminating additional testing requirements currently needed to earn that designation. This would allow pharmacists to substitute biosimilars for brand-name drugs more easily, though it would preserve the exclusive marketing period for the first biosimilar approved for each reference product.[AI-Generated]

Reported by committee 27 July 2026

Record as of 27 July 2026 — the most recent action in the official record. Status can lag; each step below carries its own date.

27 July 2026 Reported by committee
What's next: Floor scheduling (leadership decides if and when it gets a vote)
27 July 2026 Placed on calendar (Senate)
1 more action
1. 17 June 2026 Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
4 June 2025 Referred to committee
4 June 2025 Introduced in Senate

This path starts where the bill does — its first action in the official record. Routine procedural steps sit in the “more actions” rows above rather than on the main line.

Read the live feed — on the site or in the app Look up S. 1954 on Congress.gov All US bills